Company Description
Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases.
The company develops SPY001, a humanized monoclonal immunoglobulin G1 antibody that is in phase-2 clinical stage designed to bind selectively to the α4β7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn’s disease); and SPY002 and SPY072 – anti-TL1A mAbs designed to bind to tumor necrosis factor-like ligand 1A (TL1A).
It is also developing SPY003, a clinical-stage program, which is in phase-2 clinical stage designed to bind to interleukin 23 (IL-23); SPY120, a combination of anti-α4β7 and anti-TL1A mAbs; SPY130, a combination anti-α4β7 and anti-IL-23 mAbs; and SPY230, a combination anti-TL1A and anti-IL-23 mAbs.
The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023.
The company was incorporated in 2013 and is based in Waltham, Massachusetts.
| Country | United States |
| Founded | 2013 |
| IPO Date | Apr 7, 2016 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 112 |
| CEO | Cameron Turtle |
Contact Details
Address: Building 23, Suite 105 Waltham, Massachusetts 02453 United States | |
| Phone | 617 651 5940 |
| Website | spyre.com |
Stock Details
| Ticker Symbol | SYRE |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001636282 |
| CUSIP Number | 00773J202 |
| ISIN Number | US00773J2024 |
| Employer ID | 46-4312787 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Cameron Turtle DPHIL, Ph.D. | Chief Executive Officer and Director |
| Scott L. Burrows | Chief Financial Officer |
| Heidy Abreu King-Jones J.D., L.L.M. | Chief Legal Officer and Corporate Secretary |
| Dr. Sheldon Sloan M.B.E., M.D. | Chief Medical Officer |
| Dr. Janet Gunzner-Toste M.B.A., Ph.D. | Senior Vice President of Operations |
| Brian Connolly | Chief Technical Officer |
| Dr. Justin LaFountaine Ph.D. | Senior Vice President of Corporate Development |
| Melissa Cooper | Senior Vice President of People |
| Dr. James Paul Kastenmayer J.D., Ph.D. | Consultant |
| Dr. Joshua Friedman M.D., Ph.D. | Senior Vice President of Clinical Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 1, 2026 | 144 | Filing |
| Jun 26, 2026 | S-3ASR | Automatic shelf registration statement of securities of well-known seasoned issuers |
| Jun 25, 2026 | 144 | Filing |
| Jun 23, 2026 | 144 | Filing |
| Jun 23, 2026 | SCHEDULE 13D/A | Filing |
| Jun 22, 2026 | 144 | Filing |
| Jun 15, 2026 | 8-K | Current Report |
| Jun 3, 2026 | 144 | Filing |
| Jun 1, 2026 | 8-K | Current Report |
| May 29, 2026 | 8-K | Current Report |